Bavarian Nordic Receives USD 120 Million Contract for Smallpox and Mpox Vaccine Production
Collaborative Effort for Stockpile Replenishment
Contract Details
Bavarian Nordic AS, a leading biotechnology company, has been awarded a contract worth approximately USD 1568 million from the Biomedical Advanced Research and Development Authority (BARDA). The contract will enable Bavarian Nordic to replenish its stockpile of bulk vaccine required for the production and supply of freeze-dried smallpox and mpox vaccines.
Long-Standing Partnership with US Government
Since 2003, Bavarian Nordic has collaborated with the US government on the development, manufacturing, and supply of smallpox vaccines. This latest contract further strengthens this partnership.
Enhanced Vaccine Shelf-Life
The contract includes approximately USD 17 million for additional services, including support for the development of a freeze-dried version of the vaccine with an extended shelf-life. This enhanced stability will improve vaccine storage and distribution capabilities.
Conclusion
This substantial investment from BARDA underscores the ongoing commitment to safeguarding public health against smallpox and mpox. Bavarian Nordic's continued collaboration with the US government ensures the availability of vital vaccines for future pandemics and emergencies, leaving a lasting impression of preparedness and response.
Comments